Gilead Plummets on Hep C Drug

Insight on the biotech firm seeing shares down after announcing some patients treated with its hepatitis C drug experienced a relapse, with Mark Schoenebaum, ISI Group

CNBC | February 17, 2012

Tags:. .hep. .gilead. .biotech. .relapse. .plummets